Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
53.27
+0.39 (+0.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi-Aventis S.A. ADR
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
GSK Halts Late-Stage RSV Vaccine Trial In Pregnant Women
February 18, 2022
GlaxoSmithKline plc (NYSE: GSK) has paused a late-stage trial of its respiratory syncytial virus (RSV) vaccine candidate in pregnant women based on safety...
Via
Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
February 18, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO...
Via
Benzinga
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
February 18, 2022
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab...
Via
Benzinga
Hopeful Golden Cross Forms On Sanofi's Chart
February 17, 2022
If history is any guide, there may be good fortune ahead for shares of Sanofi (NASDAQ:SNY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could...
Via
Benzinga
Sanofi: Q4 Earnings Insights
February 04, 2022
Sanofi (NASDAQ:SNY) reported its Q4 earnings results on Friday, February 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Sanofi SA: An Expected Move Towards The $52.90
February 04, 2022
Today we can expect a move towards the $52.90 resistance, possibly further into the $54 price range, anticipating positive news.
Via
Talk Markets
Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use
January 28, 2022
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have
Via
Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
February 17, 2022
Can the formerly red-hot biotech segment return to its previous glory?
Via
Investor's Business Daily
3 Desirable Drug Stocks With Very Promising Pipelines
February 16, 2022
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.
Via
InvestorPlace
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
February 10, 2022
The
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Markets News for Tuesday
February 08, 2022
Oil stocks are up on huge gains.
Via
Talk Markets
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More
February 06, 2022
Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came...
Via
Talk Markets
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
February 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Sanofi Records Q4 Topline, Bottomline Growth As Blockbuster Eczema Drug Soars
February 04, 2022
Sanofi SA's (NASDAQ: SNY)
Via
Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...
Via
Benzinga
Earnings Scheduled For February 4, 2022
February 04, 2022
Companies Reporting Before The Bell • Brookfield Business (NYSE:BBU) is estimated to report earnings for its fourth quarter.
Via
Benzinga
A Preview Of Sanofi's Earnings
February 03, 2022
Sanofi (NASDAQ:SNY) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that Sanofi will likely...
Via
Benzinga
Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028
February 03, 2022
Palm Beach, FL –– February 3, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination,...
Via
FinancialNewsMedia
Exposures
COVID-19
Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics
February 02, 2022
Benzinga’s weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment.
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
February 01, 2022
After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned.
Via
Benzinga
5 Things To Expect This Week
January 31, 2022
While the "January effect" was rather disappointing, February kicks off with an important week ahead for many types of investors.
Via
InvestorPlace
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
January 31, 2022
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.
Via
Benzinga
CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation
January 31, 2022
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a posi
Via
Benzinga
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
January 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential
January 24, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 24, 2022 – USA News Group – Within the grand battle against cancer, the use of immunotherapy continues to grow at...
Via
FinancialNewsMedia
Why Jim Cramer Like NextEra Energy And Lincoln Electric?
January 21, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said NextEra Energy, Inc. (NYSE:
Via
Benzinga
Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease
January 19, 2022
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced data from the second Phase 3 trial of Dupixent (dupilumab) in...
Via
Benzinga
Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares
January 13, 2022
Key takeaways: Loss-making Connect Biopharma says Phase 3 clinical trials of its CBP-201 drug for atopic dermatitis will begin in second half of this year Connect Biopharma...
Via
Benzinga
Acasti Pharma: Bouncing Back With a New Drug Pipeline
January 04, 2022
Picture credit: Louis Reed on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.